Investor Presentation Q1 2022
14
Investor presentation First three months of 2022
ONWARDS 2 met its primary endpoint as well as demonstrated
superiority on HbA₁c reduction compared to insulin degludec
Change from baseline (%)
Superior change in HbA1c from baseline over time 26 weeks
0,0
-0,4
-0,8
-1,2
Η Η
0 2 4 6 8 10 12 14 16 18 20 22 24 26
-0.71%*
-0.93%*
•
Safety
Key highlights
Insulin icodec appeared to have a safe and well-tolerated profile
In the trial, there was no statistical difference in estimated
hypoglycaemia events
•
Potential
Completion of remaining five ONWARDS trials expected during
the remainder of 2022
ONWARDS 2 results support our belief that insulin icodec has the
potential to improve the quality of life for people living with
diabetes
Weeks
-Once-weekly insulin icodec
-Once-daily insulin degludec
Note: Overall baseline HbA1c of 8.13%
* Lines are based on observed data where the value denoted after 26 week is estimated mean value 26 derived based on multiple imputation
Novo NordiskⓇView entire presentation